Abcellera Biologics Stock Analysis

ABCL Stock  USD 4.48  0.58  14.87%   
Abcellera Biologics is undervalued with Real Value of 5.32 and Hype Value of 4.61. The main objective of Abcellera Biologics stock analysis is to determine its intrinsic value, which is an estimate of what Abcellera Biologics is worth, separate from its market price. There are two main types of Abcellera Biologics' stock analysis: fundamental analysis and technical analysis.
The Abcellera Biologics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

Abcellera Stock Analysis Notes

About 23.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.31. Some equities with similar Price to Book (P/B) outperform the market in the long run. Abcellera Biologics has Price/Earnings To Growth (PEG) ratio of 2.22. The entity recorded a loss per share of 0.64. The firm had not issued any dividends in recent years. AbCellera Biologics Inc. develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics is traded on NASDAQ Exchange in the United States. For more info on Abcellera Biologics please contact Carl Hansen at 604 559 9005 or go to https://www.abcellera.com.

Abcellera Biologics Investment Alerts

Abcellera Biologics is way too risky over 90 days horizon
Abcellera Biologics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 28.83 M. Net Loss for the year was (162.86 M) with loss before overhead, payroll, taxes, and interest of (147.35 M).
Abcellera Biologics currently holds about 868.21 M in cash with (108.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.04.
Roughly 23.0% of the company shares are held by company insiders
Latest headline from gurufocus.com: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 IOVA ...

Abcellera Biologics Upcoming and Recent Events

20th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Abcellera Biologics Thematic Classifications

In addition to having Abcellera Biologics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech Idea
Biotech
Biotechnology and pharmaceuticals production and services

Abcellera Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.34 B.

Technical Drivers

As of the 20th of July, Abcellera Biologics shows the risk adjusted performance of 0.2074, and Mean Deviation of 3.75. Abcellera Biologics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Abcellera Biologics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Abcellera Biologics is priced correctly, providing market reflects its regular price of 4.48 per share. Given that Abcellera Biologics has jensen alpha of 1.16, we suggest you to validate Abcellera Biologics's prevailing market performance to make sure the company can sustain itself at a future point.

Abcellera Biologics Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Simple Moving Average indicator is calculated by adding the closing price of Abcellera Biologics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Abcellera Biologics short-term fluctuations and highlight longer-term trends or cycles.

Abcellera Biologics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abcellera Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abcellera Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Abcellera Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Lo Andrew over a month ago
Acquisition by Lo Andrew of 238864 shares of Abcellera Biologics at 3.15 subject to Rule 16b-3
 
Carl Hansen over a month ago
Disposition of 56125 shares by Carl Hansen of Abcellera Biologics at 2.7 subject to Rule 16b-3
 
Carl Hansen over two months ago
Acquisition by Carl Hansen of 56125 shares of Abcellera Biologics at 2.7 subject to Rule 16b-3
 
Lo Andrew over three months ago
Acquisition by Lo Andrew of 91325 shares of Abcellera Biologics at 14.02 subject to Rule 16b-3
 
Thermopylae Holdings Ltd. over three months ago
Acquisition by Thermopylae Holdings Ltd. of 343631 shares of Abcellera Biologics at 2.16 subject to Rule 16b-3
 
Montalbano John S. over three months ago
Acquisition by Montalbano John S. of 25000 shares of Abcellera Biologics at 2.3 subject to Rule 16b-3
 
Montalbano John S. over three months ago
Acquisition by Montalbano John S. of 60000 shares of Abcellera Biologics at 2.3428 subject to Rule 16b-3
 
Carl Hansen over six months ago
Acquisition by Carl Hansen of 2730109 shares of Abcellera Biologics at 2.93 subject to Rule 16b-3
 
Booth Andrew over six months ago
Disposition of 500000 shares by Booth Andrew of Abcellera Biologics at 0.32 subject to Rule 16b-3
 
Veronique Lecault over six months ago
Acquisition by Veronique Lecault of 83333 shares of Abcellera Biologics at 0.19 subject to Rule 16b-3
 
Carl Hansen over six months ago
Acquisition by Carl Hansen of 56125 shares of Abcellera Biologics at 2.7 subject to Rule 16b-3
 
Booth Andrew over six months ago
Acquisition by Booth Andrew of 14000 shares of Abcellera Biologics at 14.61 subject to Rule 16b-3

Abcellera Biologics Outstanding Bonds

Abcellera Biologics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Abcellera Biologics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Abcellera bonds can be classified according to their maturity, which is the date when Abcellera Biologics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Abcellera Biologics Predictive Daily Indicators

Abcellera Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Abcellera Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Abcellera Biologics Forecast Models

Abcellera Biologics' time-series forecasting models are one of many Abcellera Biologics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Abcellera Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Abcellera Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Abcellera Biologics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Abcellera shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Abcellera Biologics. By using and applying Abcellera Stock analysis, traders can create a robust methodology for identifying Abcellera entry and exit points for their positions.
AbCellera Biologics Inc. develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics is traded on NASDAQ Exchange in the United States.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Abcellera Biologics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Idea Analyzer Now

   

Idea Analyzer

Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
All  Next Launch Module
When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.